Press release
Sarcopenia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Explore our latest breakthroughs in Sarcopenia Research. Learn more about our innovative pipeline today! @ Sarcopenia Pipeline Outlook [https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Sarcopenia Pipeline Report
* On 29 July 2025, Animuscure Inc . announced a clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.
* DelveInsight's Sarcopenia pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Sarcopenia treatment.
* The leading Sarcopenia Companies such as Biophytis, Epirium Bio, Turn Biotechnologies, Immunis, Oncocross, BPGbio, Inc. and others.
* Promising Sarcopenia Pipeline Therapies such as AMC6156 0.1mg, Bimagrumab, MK-0773, REGN1033 (SAR391786), LPCN 1148, BIO101, Olimel N12, Glucose IV, Testosterone Enanthate, Finasteride , and others.
Stay informed about the cutting-edge advancements in Sarcopenia treatments. Download for updates and be a part of the revolution in Musculoskeletal Care @ Sarcopenia Clinical Trials Assessment [https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Sarcopenia Emerging Drugs Profile
* BIO101: Biophytis
Sarconeos (BIO101) is a small molecule proto-oncogene protein c-mas-1 agonist that is administered orally. Based on results from cellular and animal studies, it is believed that Sarconeos (BIO101) stimulates biological resilience through activation of the MAS receptor and may have the potential to improve muscle function and preserve strength, mobility, and respiratory capacity in various age-related and muscular wasting conditions. The drug showed a very good safety profile at the doses of 175 mg bid and of 350 mg bid with no Serious Adverse Events (AE) related to the product in the Phase II clinical trial study. The drug is currently in Phase II stage of clinical trial evaluation for the treatment of Sarcopenia.
* MF-300: Epirium Bio
MF-300 is an orally bioavailable small molecule that reversibly binds to the Prostaglandin E2 (PGE2)-binding site of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), an enzyme that converts PGE2 to an inactive metabolite. MF-300 target engagement inhibits 15-PGDH activity, stabilizing and increasing levels of PGE2 in a cell-based assay and in vivo in skeletal muscle in preclinical studies.
In humans and rodents, 15-PGDH gene expression is elevated in muscle coincident with the onset of age-induced muscle weakness. PGE2, a lipid signaling molecule with multiple beneficial effects on the motor unit, including enhanced muscle quality and improved function of the neuromuscular junction, is reduced in skeletal muscle of aged mice due to increased activity of 15-PGDH. Inhibiting 15-PGDH in aged muscle may be a strategy to increase physiologic levels of PGE2 to improve muscle quality and function. Currently, the drug is in the Phase I stage of its development for the treatment of Sacropenia.
* TRN005: Turn Biotechnologies
TRN-005 is a unique formulation to restore muscle mass and strength, and reverse age-related conditions that compromise people's ability to lead active lifestyles. Preclinical results demonstrated improvement in stem cell growth and differentiation, acceleration of muscle recovery, increases in fiber thickness and force output. The drug is currently in Preclinical stage of development for the treatment of Sarcopenia.
The Sarcopenia Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Sarcopenia with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sarcopenia Treatment.
* Sarcopenia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Sarcopenia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sarcopenia market.
Learn more about Sarcopenia Drugs opportunities in our groundbreaking Sarcopenia research and development projects @ Sarcopenia Unmet Needs [https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Sarcopenia Companies
Biophytis, Epirium Bio, Turn Biotechnologies, Immunis, Oncocross, BPGbio, Inc. and others.
Sarcopenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Sarcopenia Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Sarcopenia Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Discover the latest advancements in Sarcopenia treatment by visiting our website. Stay informed about how we're transforming the future of Musculoskeletal @ Sarcopenia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Sarcopenia Pipeline Report
* Coverage- Global
* Sarcopenia Companies- Biophytis, Epirium Bio, Turn Biotechnologies, Immunis, Oncocross, BPGbio, Inc. and others.
* Sarcopenia Pipeline Therapies- AMC6156 0.1mg, Bimagrumab, MK-0773, REGN1033 (SAR391786), LPCN 1148, BIO101, Olimel N12, Glucose IV, Testosterone Enanthate, Finasteride , and others.
* Sarcopenia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Sarcopenia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Sarcopenia Pipeline on our website @ Sarcopenia Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Sarcopenia Overview
* Sarcopenia Pipeline Therapeutics
* Sarcopenia Therapeutic Assessment
* Sarcopenia - DelveInsight's Analytical Perspective
* Mid Stage Sarcopenia Products (Phase II)
* BIO101: Biophytis
* Early Stage Sarcopenia Products (Phase I)
* MF-300: Epirium Bio
* Preclinical Stage Products
* TRN005: Turn Biotechnologies
* Inactive Sarcopenia Products
* Sarcopenia Companies
* Sarcopenia Key Products
* Sarcopenia Unmet Needs
* Sarcopenia Market Drivers and Barriers
* Sarcopenia- Future Perspectives and Conclusion
* Sarcopenia Analyst Views
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=sarcopenia-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/sarcopenia-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Sarcopenia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4163904 • Views: …
More Releases from ABNewswire
Major depressive disorder Market Outlook 2034 - Clinical Trials, Market Size, Me …
According to DelveInsight, the Major Depressive Disorder Treatment Market Size in the 7MM was approximately USD 7,165 million in 2023.
Major depressive disorder Market Summary
According to DelveInsight, there were ~44 million diagnosed cases of Major Depressive Disorder (MDD) across the 7MM in 2023. The US led the market, valued at ~USD 5.6 billion, projected to grow at a 4.8% CAGR through 2034. Current treatments include VRAYLAR, AUVELITY, SPRAVATO, and REXULTI, with…
Short Bowel Syndrome Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, F …
DelveInsight's, "Short Bowel Syndrome Pipeline Insight 2025" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Short Bowel Syndrome pipeline landscape. It covers the Short Bowel Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Short Bowel Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest…
Ischemic Stroke Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Ap …
DelveInsight's, "Ischemic Stroke Pipeline Insight, 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the Ischemic Stroke pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ischemic Stroke pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment…
Psoriasis Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approval …
DelveInsight's "Psoriasis Pipeline Insight, 2025" report provides comprehensive insights about 65+ companies and 75+ pipeline drugs in the Psoriasis pipeline landscape. It covers the Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Psoriasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Psoriasis Research. Learn more…
More Releases for Sarcopenia
Sarcopenia Market Size, Share & Growth Analysis 2034
Sarcopenia Market Overview
Sarcopenia is a condition characterized by the progressive loss of muscle mass, strength, and function, primarily affecting the elderly. This decline leads to increased frailty, higher risk of falls, and diminished quality of life. The rising global geriatric population has heightened the prevalence of sarcopenia, making it a significant public health concern. Consequently, there is a growing demand for effective treatments and interventions to manage and mitigate the…
Sarcopenia Treatment Market Future Prediction Report By 2030
Sarcopenia Treatment Market business research report assesses the current as well as upcoming performance of the market, also brand-new trends in the market. It provides product overview and highlights of product and application segments of the market including price, revenue, sales, sales growth rate, and market share by product. The market statistics within the report is displayed in a statistical format to offer a better understanding upon the market dynamics.…
Sarcopenia Treatment Market Report 2024 - Sarcopenia Treatment Market Size And G …
"The Business Research Company recently released a comprehensive report on the Global Sarcopenia Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The sarcopenia treatment market…
Sarcopenia Pipeline Insights Report 2023 (Updated)
(Albany, United States) As per DelveInsight's assessment, globally, the Sarcopenia Pipeline constitutes 8+ key companies continuously working towards developing 10+ Sarcopenia Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Sarcopenia Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Sarcopenia NDA approvals (if any), and product…
Global Sarcopenia Therapeutic Market Research Report 2023
The global Sarcopenia Therapeutic market was valued at US$ 2867.6 million in 2022 and is anticipated to reach US$ 3484.4 million by 2029, witnessing a CAGR of 3.3% during the forecast period 2023-2029.
view full report
https://reports.valuates.com/market-reports/QYRE-Auto-13K14453/global-sarcopenia-therapeutic
Sarcopenia Therapeutic Market
Sarcopenia is a syndrome caused by continuous loss of skeletal muscle mass, strength, and function.
The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
China is the largest consumption region of…
Sarcopenia - Drug Pipeline Landscape, 2022
Sarcopenia is a condition characterized by the loss of muscle mass and strength. It can occur due to a variety of reasons, including aging, inactivity, and certain chronic diseases.
Aging is the most common cause of sarcopenia. As people age, they tend to become less active and lose muscle mass. This process is known as age-related muscle loss or sarcopenia with aging.
Inactivity can also lead to sarcopenia. People who are not…
